bioMérieux Announces the CE Marking of Its Molecular Biology ARGENE® Test for the Simultaneous Detection of SARS-CoV-2, Inf...
bioMérieux (Paris:BIM), a world leader in the field of in vitro
diagnostics, has announced the expansion of its ARGENE® range for
the real-time PCR (RT-PCR) detection of SARS-CoV-2: the SARS-COV-2
RESPI R-GENE® test has received CE marking and is now commercially
This high-throughput test, which can be used on molecular
biology platforms in hospital laboratories and private
laboratories, allows the simultaneous (multiplex) detection of
SARS-CoV-2 and influenza viruses A and B. In addition, it includes
a cellular control to check the quality of the sample, providing an
important clinical advantage in the context of the pandemic and
large-scale sample collection at many different sites. In a single
kit, this new test comes with a second RT-PCR analysis performed
from the same extraction, for the detection of two other pathogens
that often circulate at the same time and are particularly
implicated in respiratory diseases affecting children and seniors:
RSV (human respiratory syncytial virus) and hMPV (human
metapneumovirus). hMPV is more rarely included in testing
“Infections caused by respiratory viruses often have similar
symptoms, but patient management may differ. Multiplex tests have a
key role to play with the onset of winter and the flu season.
Although the circulation of flu viruses is low to date, in light of
the COVID-19 pandemic, it is even more important to detect other
diseases associated with respiratory disease early on, especially
for high-risk patient groups. This makes it possible to adapt
clinical management and limit the circulation of these viruses,”
explained François Lacoste, Executive VP, R&D.
The SARS-COV-2 RESPI R-GENE® test will be available in Europe
and in countries that recognize the CE marking.
About the ARGENE® SARS-COV-2 R-GENE® test : As for all
tests in the ARGENE® range, the SARS-COV-2 RESPI R-GENE® may be
performed by any laboratory using PCR technology on
commercially-available nucleic acid extraction and amplification
platforms. Results are delivered in 4 to 5 hours, and a large
number of patient samples may be processed simultaneously.
The entire ARGENE® range for the detection of SARS-CoV-2 is
produced in France at the bioMérieux site in Verniolle
ABOUT BIOMÉRIEUX Pioneering Diagnostics A world leader in
the field of in vitro diagnostics for over 55 years, bioMérieux is
present in 44 countries and serves more than 160 countries with the
support of a large network of distributors. In 2019, revenues
reached €2.7 billion, with over 90% of international sales.
bioMérieux provides diagnostic solutions (systems, reagents,
software and services) which determine the source of disease and
contamination to improve patient health and ensure consumer safety.
Its products are mainly used for diagnosing infectious diseases.
They are also used for detecting microorganisms in agri-food,
pharmaceutical and cosmetic products.
bioMérieux is listed on the Euronext Paris stock market. Symbol:
BIM – ISIN Code: FR0013280286 Reuters: BIOX.PA/Bloomberg:
Corporate website: www.biomerieux.com.
version on businesswire.com: https://www.businesswire.com/news/home/20201215006029/en/
Investor Relations bioMérieux Franck Admant +33 4
78 87 20 00 email@example.com
Media Relations bioMérieux Olivier Rescaniere +33
4 78 87 20 00 firstname.lastname@example.org
Image Sept Laurence Heilbronn +33 1 53 70 74 64
Claire Doligez +33 1 53 70 74 48 email@example.com